Ann Janssens
Overview
Explore the profile of Ann Janssens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
2232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharman J, Egyed M, Jurczak W, Skarbnik A, Pagel J, Flinn I, et al.
Leukemia
. 2024 Dec;
39(2):529.
PMID: 39627506
No abstract available.
2.
Vergote V, Verhoef G, Janssens A, Woei-A-Jin F, Deckers W, Laenen A, et al.
J Nucl Med
. 2024 Nov;
65(12):1876-1883.
PMID: 39510587
Baseline metabolic tumor volume (MTV) is a promising prognostic marker in diffuse large B-cell lymphoma (DLBCL). We assessed the prognostic value of 4 novel metabolic risk scores in a real-life...
3.
Mylemans M, Boeckx N, Janssens A, Tajdar M, Van Laer C
Int J Lab Hematol
. 2024 Sep;
47(1):186-188.
PMID: 39227009
No abstract available.
4.
Furstenau M, Kater A, Robrecht S, von Tresckow J, Zhang C, Gregor M, et al.
Lancet Oncol
. 2024 May;
25(6):744-759.
PMID: 38821083
Background: In the primary analysis report of the GAIA/CLL13 trial, we found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib improved undetectable measurable residual disease (MRD) rates and progression-free survival compared with chemoimmunotherapy in...
5.
Kater A, Owen C, Moreno C, Follows G, Munir T, Levin M, et al.
NEJM Evid
. 2024 Feb;
1(7):EVIDoa2200006.
PMID: 38319255
BACKGROUND: GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-venetoclax in older patients and/or those with comorbidities with previously untreated chronic lymphocytic leukemia (CLL). METHODS: We...
6.
Pott C, Jurinovic V, Trotman J, Kehden B, Unterhalt M, Herold M, et al.
J Clin Oncol
. 2023 Dec;
42(5):550-561.
PMID: 38096461
Purpose: We report an analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier:...
7.
Niemann C, Munir T, Moreno C, Owen C, Follows G, Benjamini O, et al.
Lancet Oncol
. 2023 Nov;
24(12):1423-1433.
PMID: 37944541
Background: In the GLOW study, fixed-duration ibrutinib-venetoclax showed superior progression-free survival versus chlorambucil-obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both, at...
8.
Visentin A, Chatzikonstantinou T, Scarfo L, Kapetanakis A, Demosthenous C, Karakatsoulis G, et al.
Am J Hematol
. 2023 Sep;
98(12):1856-1868.
PMID: 37772428
In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B...
9.
Nastoupil L, Hess G, Pavlovsky M, Danielewicz I, Freeman J, Garcia-Sancho A, et al.
Blood Adv
. 2023 Sep;
7(22):7141-7150.
PMID: 37722354
The phase 3 SELENE study evaluated ibrutinib + chemoimmunotherapy (CIT; bendamustine and rituximab [BR]; or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) for patients with relapsed/refractory (R/R) follicular lymphoma (FL)...
10.
Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, et al.
J Clin Oncol
. 2023 Jun;
41(21):3689-3699.
PMID: 37279408
Purpose: In GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). The current analysis describes...